Evidence map›Paper›PMID 21098758›Full record

ArticleJournal of the National Cancer Institute2010

Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort.

Mahboobeh Safaeian, Koen Quint, Mark Schiffman, Ana Cecilia Rodriguez, Sholom Wacholder, Rolando Herrero, Allan Hildesheim, Raphael P Viscidi, Wim Quint, Robert D Burk

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Clinical significance ofFrontiers in cellular and infection microbiology · 2026
    Article
  6. Review
  7. Microorganisms · 2023
    Review
  8. Iranian journal of public health · 2022
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Frequency ofInfectious agents and cancer · 2017
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Mahboobeh SafaeianDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA. safaeianm@mail.nih.gov
Koen Quint
Mark Schiffman
Ana Cecilia Rodriguez
Sholom Wacholder
Rolando Herrero
Allan Hildesheim
Raphael P Viscidi
Wim Quint
Robert D Burk
National Cancer Institute · USInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRDDL Diagnostic Laboratory · NLNational Cancer Institute · UANational Institutes of Health · USYeshiva University · US

Funding

PERSISTENT HUMAN PAPILLOMAVIRUS IN WOMEN AT RISK FOR CERVIX CANCERU01CA078527 · NCI · YESHIVA UNIVERSITY · PI BURK, ROBERT D · 2003 to 2018
$8.6M
Immune responses to HPV infection and HPV vaccinationZIACP010216 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI HILDESHEIM, ALLAN · 2010 to 2020
$6.5M
PERSISTENT HPV IN WOMEN AT RISK FOR CERVIX CANCERR01CA078527 · NCI · YESHIVA UNIVERSITY · PI BURK, ROBERT D. · 1998 to 2002
$1.5M
GUANACASTE PROJECT--A POPULATION BASED NATURAL HISTN01CP081023 · CP · FUNDACION COSTARRICENSE PARA LA DOCENCIA · PI BRATTI, CONCEPCION C · 1998 to 2000
$1.4M
POPULATION-BASED NATURAL HISTORY OF CERVICAL NEOPLASIAN01CP021081 · CP · FUNDACION COSTARRICENSE PARA LA DOCENCIA · PI PACHECO, MARIO · 1992 to 1993
–
POPULATION BASED NATURAL HISTORY OF CERVICAL NEOPLASIAN01CP050535 · CP · FUNDACION COSTARRICENSE PARA LA DOCENCIA · PI BRATTI, CONCEPCION C · 1995 to 1998
–
POPULATION-BASED NATURAL HISTORY OF CERVICAL NEOPLASIAN01CP040542 · CP · FUNDACION COSTARRICENSE PARA LA DOCENCIA · PI BRATTI, CONCEPCION · 1994 to 1994
–
POPULATION-BASED NATURAL HISTORY OF CERVICAL NEOPLASIAN01CP033061 · CP · FUNDACION COSTARRICENSE PARA LA DOCENCIA · PI PACHECO, MARIO · 1993 to 1994
–
NCI NIH HHS CA78527NCI NIH HHS N01-CP-21081NCI NIH HHS N01-CP-33061NCI NIH HHS N01-CP-40542NCI NIH HHS N01-CP-50535NCI NIH HHS N01-CP-81023NCI NIH HHS R01 CA078527NCI NIH HHS U01 CA078527
6 · The paper itself

Abstract

backgroundCofactors might affect the risk of the rare progression from infection with carcinogenic human papillomavirus (HPV) to cervical premalignancy to invasive cancer. Some studies have observed that Chlamydia trachomatis infection is associated with increased risk for cervical cancer. In a large prospective cohort, we assessed the role of C trachomatis in cervical premalignancy and addressed confounding by HPV.

methodsWe identified 182 women with prevalent and 132 women with incident histological cervical intraepithelial neoplasia grade 2 (CIN2), grade 3 (CIN3), or cervical cancer (CIN2+) in the Costa Rica HPV Natural History Study. Control subjects were 995 (approximately 10% of the 10 049) subjects who were randomly selected from the same study. Cervical HPV status at enrollment was determined by MY09/MY11 polymerase chain reaction amplification and dot-blot hybridization. The presence of C trachomatis DNA in cervical exfoliated cells at enrollment was determined by a novel serovar-specific polymerase chain reaction-based C trachomatis detection and genotyping assay. Plasma drawn at enrollment from each subject was used to determine C trachomatis immunoglobulin G (IgG) status. Logistic regression was used to examine the association between C trachomatis and CIN2+, taking into account possible confounding by HPV.

resultsC trachomatis positivity at enrollment was associated with CIN2+ and concurrent and subsequent carcinogenic HPV infection. To account for confounding by HPV status, we restricted the analysis to women positive for carcinogenic HPV DNA at enrollment and found no association between C trachomatis status (as assessed by DNA or IgG) at enrollment and combined prevalent and/or incident CIN2+ (for C trachomatis DNA positivity, odds ratio = 0.77, 95% confidence interval = 0.42 to 1.41; for C trachomatis seropositivity, odds ratio = 1.09, 95% confidence interval = 0.85 to 1.41).

conclusionsWe found no association between C trachomatis status, as assessed by DNA or IgG, and risk of cervical premalignancy, after controlling for carcinogenic HPV-positive status. Previous positive associations between C trachomatis and cervical premalignancy could have been caused, in part, by an increased susceptibility to HPV infection.

Indexed as

AdultChlamydia InfectionsChlamydia trachomatisCohort StudiesConfidence IntervalsConfounding Factors, EpidemiologicDNA, BacterialDNA, ViralEnzyme-Linked Immunosorbent AssayFemaleGenotypeHuman papillomavirus 16HumansImmunoglobulin AImmunoglobulin GIncidenceDNA, BacterialDNA, ViralImmunoglobulin AImmunoglobulin G

Identifiers

PMID21098758
PMCPMC2994864
OpenAlexW2141513061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.